Organization
Mundipharma Research
5 clinical trials
1 abstract
Clinical trial
A Phase 1, Multicentre, Open-Label Study to Evaluate the PK, Safety, and Tolerability of a Single IV Dose of Rezafungin in Paediatric Subjects, Receiving Systemic Antifungals as Prophylaxis for IFI or to Treat a Suspected or Confirmed FIStatus: Recruiting, Estimated PCD: 2027-03-01
Clinical trial
A Phase 2, Proof-of-Concept, Multicentre, Open-Label, Randomised, Active-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Rezafungin Combined With 7 Days of Co-Trimoxazole Versus Co-Trimoxazole Monotherapy in HIV-Infected Adults With Pneumocystis Jirovecii PneumoniaStatus: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
A Phase 1 Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Tinostamustine, a Novel Alkylating and Deacetylase Inhibiting Molecule, as Adjuvant Treatment in Patients With Newly Diagnosed Unmethylated MGMT-promoter GlioblastomaStatus: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
A Phase 1 Trial to Investigate the Safety, Pharmacokinetic Profiles and the Efficacy of Tinostamustine, a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule, in Relapsed/Refractory Hematologic MalignanciesStatus: Active (not recruiting), Estimated PCD: 2023-11-01
Clinical trial
A Phase 1/2 Study to Investigate the Safety, Pharmacokinetics and Efficacy of EDO-S101, a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule, in Patients With Advanced Solid TumorsStatus: Completed, Estimated PCD: 2022-07-27
Abstract
A phase II study of tinostamustine in patients (pts) with advanced solid tumours.Org: Mary Crowley Cancer Research, University of Michigan, European Institute of Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy, Gynaecologic Cancer Programme, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d’Hebron, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain,